Solv4U

Solv4U
Product Description

Poor water solubility of drug candidates is one of the most common hurdles pharmaceutical development is confronted with. Promising new chemical entities and drug candidates often fail in development due to the limitations of their solubility in water.

Marinomed Biotech AG provides Solv4U technology partnerships to address solubility and bioavailability issues and to support formulation development of Active Pharmaceutical Ingredients (APIs) in all stages of drug discovery based on its proprietary innovative Marinosolv® technology platform.

Read more Show less

Marinomed Biotech AG

  • AT
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Research Organisation
Laboratory Services
Medical Devices
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Sales Markets
Show more Show less

Marinomed Biotech AG

  • AT
  • 2020
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
Contract Research Organisation
Laboratory Services
Medical Devices
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Marinomed Biotech AG (1)

  • Budesolv

    Product Budesolv

    novel preservative-free budesonide nasal spray, IP protected formulation

Marinomed Biotech AG resources (1)

  • Marinosolv® - A Novel Approach to Increase the Solubility and Improve the Bioavailability of Promising Low-Soluble Drugs

    Whitepaper Marinosolv® - A Novel Approach to Increase the Solubility and Improve the Bioavailability of Promising Low-Soluble Drugs

    80-90% of promising, highly potent drug candidates in the R&D pipeline fail due to their low solubility in aqueous formulations, and subsequently their low bioavailability.The solubility of a drug in aqueous formulations is a critical factor for the permeability and thereby bioavailability and systemic absorption into sensitive target tissues and/or at the site of action. Therefore, several different chemical and physical approaches to increase the solubility of a drug in aqueous formulations have become available in the last decade. One of them is Marinosolv®, a formulation technology that provides effective solubilization for a variety of highly hydrophobic small molecules and peptides, including APIs/NCEs.